The Use of Laser-Assisted Indocyanine Green Dye Angiography to Predict Mastectomy Skin Flap Viability (ICG)
|ClinicalTrials.gov Identifier: NCT01554267|
Recruitment Status : Unknown
Verified May 2014 by Duc T Bui, MD, Stony Brook University.
Recruitment status was: Recruiting
First Posted : March 14, 2012
Last Update Posted : May 13, 2014
In the investigators previous study of 51 breast reconstructions (32 patients), we compared three different assessments of vascular perfusion of tissue; clinical judgment, fluorescein dye angiography (FDA) and laser-assisted indocyanine green dye angiography (ICG). Because tissue with poor perfusion becomes necrotic and can compromise the success of breast reconstruction, it is important that tissue with poor perfusion be removed at the time of the reconstructive surgery. However, it is also important to remove the least amount of potentially necrotic tissue as possible so that the breast reconstruction is not compromised by lack of skin. Therefore finding the best way to assess potentially necrotic tissue is a vital clinical question. In the initial study the 3 different assessment methods which were made at the time of surgery were compared to the subsequent development of necrotic tissue.
In the initial study, clinical judgment was the basis for determining the tissue removed because it had the potential to become necrotic. The investigators collected data with the FDA system and ICG system, but this data was not used in making the clinical decisions. The study followed the progression of tissue to overt necrosis and this clinical outcome was then compared to the predictions made by the three different assessment strategies. The investigators found that clinical judgment failed to detect tissue which subsequently became necrotic in 21 out of 51 instances for a failure rate of 41%. The FDA system predicted larger areas of potentially necrotic tissue than clinical judgment, but was found to over-predict the area that became necrotic by 82% - 88% (88% if all cases were included and 82% if only those cases which subsequently developed necrosis were included). Although the ICG system is similar to the FDA system in that a dye is used to assess perfusion, the ICG system has enhanced software which improves the estimated perfusion. The ICG system provided 90% sensitivity and 100% specificity in the predicted vs. actual necrotic tissue at specific absolute perfusion units values.
Hypothesis: Using the values of absolute perfusion units discovered in the previous study and implementing its use in the operating room will decrease all-inclusive necrosis rates to below 10%, reflecting a 31% decrease in the investigators necrosis rate.
|Condition or disease||Intervention/treatment|
|Breast Cancer Breast Reconstruction Mastectomy||Device: Laser-Assisted ICG Dye Angiography (SPY System)|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||45 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Use of Laser-Assisted Indocyanine Green Dye Angiography to Predict Intraoperative Mastectomy Skin Flap Viability During Breast Reconstruction|
|Study Start Date :||January 2014|
|Estimated Primary Completion Date :||January 2015|
|Estimated Study Completion Date :||May 2015|
Experimental: Mastectomy Skin Flap SPY Excision
Single arm study where areas of necrosis predicted by Laser-Assisted Indocyanine Green Dye Angiography (SPY system) will be excised intraoperatively during breast reconstruction surgery.
Device: Laser-Assisted ICG Dye Angiography (SPY System)
7.5-10mg of ICG dye will be injected at 2 different time points during breast reconstruction with the assistance of the SPY system to determine areas of skin with poor blood flow. These areas are excised during the operation in order to decrease postoperative complications including mastectomy skin flap necrosis and reconstruction failure.
- Mastectomy Skin Flap Necrosis [ Time Frame: 30 days postop ]All-inclusive mastectomy skin flap necrosis including: epidermolysis, partial/superficial necrosis, and full-thickness necrosis.
- Infection [ Time Frame: 30 days postop ]Superficial, Deep or Organ space surgical site infection as defined by the CDC. Patients treated with oral or IV antibiotics will be documented, including patients who have loss of implant due to infection.
- Wound Dehiscence or Implant Extrusion [ Time Frame: 30 days postop ]Wound breakdown and exposure of acellular dermal matrix and implant will be documented.
- Seroma/Hematoma [ Time Frame: 30 days postop ]Any evidence of seroma/hematoma will be documented and be documented based on requirement of a surgical intervention or observation.
- Removal or Loss of Implant [ Time Frame: 30 days postop ]Patients who require removal of their implants will be documented along with the primary cause of their loss of implant.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01554267
|Contact: Brett T Phillips, MDemail@example.com|
|Contact: Sami U Khan, MDfirstname.lastname@example.org|
|United States, New York|
|Stony Brook University||Recruiting|
|Stony Brook, New York, United States, 11794|
|Principal Investigator:||Duc T Bui, MD||Stony Brook University|
|Study Director:||Brett T Phillips, MD||Stony Brook University|